This article is more than 5 years old. Information may no longer be current.
Brien Holden Vision Institute to launch commercial entities
Click Here to Manage Email Alerts
The Brien Holden Vision Institute is in the process of bringing to market advanced products for myopia and myopia control, presbyopia, and the detection and management of potentially blinding eye disease, the institute reported in a press release.
For more than 20 years the Brien Holden Vision Institute (BHVI) has funded its programs through research support from the Australian and U.S. governments, grants, collaborators, corporations and royalties from its breakthrough products, BHVI reported.
The BHVI will remain a nonprofit, noncommercial science, translational research, licensing and humanitarian organization, the group said, but “The Brien Holden Vision subsidiaries are constituted and will be resourced to be successful commercial companies that will support the institute’s goals through revenue generation and product delivery.”
The institute’s myopia products are being developed to tackle the global health and economic issue as well as macular degeneration associated with high myopia, according to the release. Its new extended depth of focus technologies aim to provide good vision for all distances and positions of gaze in both contact lens and IOL form.
These products “will be brought to market through Brien Holden Vision Pty. Ltd. and selected collaborating organizations for key opinion leader trials in 2015,” the release stated.
The BHVI has also purchased a controlling interest in a U.S. company to establish Brien Holden Vision Diagnostics to address early detection and intervention of diabetic retinopathy. The diagnostic group’s retinal imaging system is a “high-resolution, tri-stimulus, self-focusing, stereoscopic retinal imaging camera that is easy to operate,” according to the release.
The same team is also developing a device to rapidly diagnose concussion and other mild traumatic brain injuries.